The isolation of many other RBD-targeted neutralizing Abs from COVID-19 convalescent patients (22–28) and the demonstration that they provide in vivo protection against SARS-CoV-2 challenge in small animals and nonhuman primates (25, 29–31) showed that the RBD is the major target of neutralizing Abs upon natural CoV infection. This evidence concerns the gene DDX41 and COVID-19.